Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    Immunotherapy with hLL1-DOX
Show Display Options
Rank Status Study
1 Recruiting Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: hLL1-DOX (IMMU-115)

Indicates status has not been verified in more than two years